EUVIMEDEUVIMED entdecken
Crossref

Evaluation of The Rationality of Dengue Hemorrhagic Fever (DHF) Treatment in Inpatients at Rsi Siti Aisyah Madiun in The 2024 Period

Djembor Sugeng Walujo, Fitria Wahyuning Wulan, Azrena Tasya Nur Afifah

Journal of Natural Products and Drug Development · 2025

DOI: 10.58723/jnpdd.v1i1.43 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Natural Products and Drug Development, 2025. Verfasst von Djembor Sugeng Walujo und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background of Study: Drug rationality is an important aspect to ensure the achievement of therapeutic effects and improve the quality of life of patients with the criteria of the right drug, right dose, right diagnosis and right indication. Meanwhile, thet use oft a drugt is saidt to bet irrationalt if thet possibilityt of negativet impactst receivedt by thet patientt is greatert than its benefitstt.Aims and Scope of Paper: This study aimst to determine the descriptiont of the rationalityt of Denguet Hemorrhagict Fevert (DHF) treatment in hospitalized patients at RSI Siti Aisyah Madiun in terms of the right drug, right dose, right diagnosis, and right indication.

Method

The study used was an observationalt study conductedt retrospectively with univariate analysis and purposive sampling techniques.

Results

The use of drugs for Dengue Hemorrhagic Fever (DHF) from the electrolyte fluid group, namely asering infusion 22.56%, RL infusion 33.83%, NS infusion 23.31%, D5 infusion 0.45% 20.30%, and for the antipyretic group, namely paracetamol 100%, for the antiemetic group, namely ondansetron 67.67%, metoclopramide 32.33% while from the supplement and vitamin group, namely curcuma 77.44% and psidii 22.56%. The rationality of drug use includes 100% correct drug, 97.74% correct dose, and 100% correct diagnosis and 100% correct indication.

Conclusion

Based on the variables tested, thet rationalityt of the uset of drugs for Dengue Hemorrhagict Fevert (DHF) has met the criteria for rationality of treatment.

Zitieren

APA

Walujo, D. S., Wulan, F. W., & Afifah, A. T. N. (2025). Evaluation of The Rationality of Dengue Hemorrhagic Fever (DHF) Treatment in Inpatients at Rsi Siti Aisyah Madiun in The 2024 Period. Journal of Natural Products and Drug Development. https://doi.org/10.58723/jnpdd.v1i1.43

Vancouver

Walujo DS, Wulan FW, Afifah ATN. Evaluation of The Rationality of Dengue Hemorrhagic Fever (DHF) Treatment in Inpatients at Rsi Siti Aisyah Madiun in The 2024 Period. Journal of Natural Products and Drug Development. 2025. doi:10.58723/jnpdd.v1i1.43

BibTeX
@article{Walujo2025,
  author = {Walujo, Djembor Sugeng and Wulan, Fitria Wahyuning and Afifah, Azrena Tasya Nur},
  title = {Evaluation of The Rationality of Dengue Hemorrhagic Fever (DHF) Treatment in Inpatients at Rsi Siti Aisyah Madiun in The 2024 Period},
  journal = {Journal of Natural Products and Drug Development},
  year = {2025},
  doi = {10.58723/jnpdd.v1i1.43}
}
Kostenlos starten →